文献速递角膜与眼表疾病小儿眼科与斜弱视

儿童春季角结膜炎免激素局部治疗有效性的AAO报告

Effectiveness of Corticosteroid-Sparing Topical Treatments for Vernal Keratoconjunctivitis in Children: A Report by the American Academy of Ophthalmology.
PubMed 文献 · Ophthalmology · 2026-03-09

美国眼科学会(AAO)基于PubMed截至2025年8月的文献,系统评估了18岁及以下儿童春季角结膜炎(VKC)的免激素局部治疗。I级与III级证据均显示环孢素、他克莫司、色甘酸钠和干扰素α-2b可改善VKC体征与症状,且除用药部位不适外未报告显著不良事件;多数I级证据支持钙调神经磷酸酶抑制剂环孢素和他克莫司。

要点

  • I级与III级证据均显示免激素局部治疗可改善儿童VKC的体征和症状。
  • 多数I级证据支持使用钙调神经磷酸酶抑制剂环孢素与他克莫司。
  • 除用药部位不适外,纳入研究报告无显著不良事件。

核心结论

  • I级和III级证据表明,环孢素、他克莫司、色甘酸钠和干扰素α-2b等免激素局部干预可改善儿童VKC的临床体征和症状。
  • 多数I级证据支持使用钙调神经磷酸酶抑制剂——环孢素和他克莫司。

研究设计与样本

  • 美国眼科学会(AAO)报告,采用PubMed数据库文献检索,末次检索时间为2025年8月,限英文文献且无发表时间限制。

主要发现

  • I级证据评估的药物包括环孢素(4/6)、他克莫司(4/6)、干扰素α-2b(1/6)和色甘酸钠(1/6)眼用制剂。
  • III级证据研究多数(5/9)报告了他克莫司滴眼液或眼膏的治疗结果。
  • 无论药物、浓度、给药频率或治疗时长如何,纳入的I级与III级证据均显示干预可改善儿童VKC的体征和症状。
  • 除用药部位不适外,研究报告无显著不良事件。

关键数值与推荐

  • 纳入标准为评估18岁及以下儿童VKC免激素局部治疗疗效的已发表文献。
  • 证据分级结果:I级6项、III级9项;I级证据中环孢素4/6、他克莫司4/6、干扰素α-2b 1/6、色甘酸钠1/6。
  • III级证据研究中5/9评估他克莫司滴眼液或眼膏。

临床怎么用

  • 对儿童VKC可考虑使用环孢素、他克莫司、色甘酸钠或干扰素α-2b等免激素局部治疗以改善体征和症状。
  • 基于多数I级证据,钙调神经磷酸酶抑制剂环孢素和他克莫司是优先考虑的免激素局部选择。
  • 用药时需关注用药部位不适,但纳入研究报告除该不适外无显著不良事件。

局限性

  • 本文为文献综述与证据分级报告,未开展新的原始研究。
  • 纳入文献仅来自PubMed且限英文发表,可能存在检索与语言偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To review the published literature assessing the efficacy of corticosteroid-sparing topical treatments for vernal keratoconjunctivitis (VKC) in children 18 years of age and younger. METHODS: A literature search of the PubMed database was last conducted in August 2025 and limited to articles published in English without date restrictions. The search yielded 56 articles, which were reviewed by the primary author in abstract form; 24 were selected for full-text review. Fifteen articles met the inclusion criteria and were assigned a level of evidence rating by the panel methodologist. RESULTS: Six studies were rated level I, and 9 studies were rated level III. Level I evidence evaluated the efficacy of cyclosporine (4/6), tacrolimus (4/6), interferon alpha-2b (1/6), and sodium cromoglycate (1/6) ophthalmic preparations. Most level III evidence studies (5/9) reported outcomes using tacrolimus drops or ointment. Regardless of the medication, concentration, dosing frequency, or treatment duration, level I and level III evidence included in the assessment demonstrated that signs and symptoms of VKC in children can be improved with intervention. Apart from application site discomfort, the studies reported no significant adverse events. CONCLUSIONS: Level I and III evidence demonstrate that treatment with corticosteroid-sparing topical interventions such as cyclosporine, tacrolimus, sodium cromoglycate, and interferon alpha-2b can improve clinical signs and symptoms of VKC in children. Most of the level I evidence supports the use of the calcineurin inhibitors-cyclosporine and tacrolimus. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Cavuoto KM, Oatts JT, Nallasamy S, et al. Effectiveness of Corticosteroid-Sparing Topical Treatments for Vernal Keratoconjunctivitis in Children: A Report by the American Academy of Ophthalmology. Ophthalmology. 2026. PMID: 41801166. doi:10.1016/j.ophtha.2026.01.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。